Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Inclusion Criteria: * Patient with CIPN manifested by painful symptoms such as numbness and / or tingling and / or burning pain in fingers / hands and toes / feet with a typical distribution in "gloves and socks" beginning after neurotoxic chemotherapy * Painful CIPN as expressed by the BPI-SF (average pain) as ≥ 4/10 * CIPN persisting at least 1 month after completion of chemotherapy with taxanes and/or platinum salts and sensory CIPN grade ≥ 2 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v.5.0) grading scale * Stable doses in the 4 weeks before screening, of concomitant neuropathic pain medication (antiepileptic drugs) * Healthy and non-irritated skin on the areas to be treated * Absence of neurotoxic chemotherapy planned during the next 6 months after inclusion * Patient affiliated to a social security scheme * \> 18 years old * Signed written informed consent form Exclusion Criteria: * Presence of known carcinomatous meningitis * Pre-existing known peripheral neuropathy of another aetiology (alcohol, diabetes, …) * Hypersensitivity to Capsaicin or contra-indications to duloxetine (e.g imatinib, tamoxifen) * Patient already treated for this neuropathy with Capsaicin patches * Patient treated by antidepressant drugs at time of inclusion * Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 90 mmHg) or recent history (\<3 months) of cardiovascular events (stroke, heart attack, pulmonary embolism) * Patients with known severe renal or hepatic failure * Breastfeeding or pregnant women * Persons deprived of liberty or guardianship (including curatorship) * Patient unable to undergo regular medical follow-up for geographical, social or psychological.